TICKERNERD
Menu
LEXXLEXXHealthcare · Biotechnology

LEXX Stock Forecast: Lexaria Bioscience Corp. Price Predictions for 2026-2027

Last close, 4 Sept 2026
$14
+14.85% on the day

The 1 Wall Street analysts covering Lexaria Bioscience Corp. hold a median 12-month price target of $52 — +271.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 5 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$23.4M
Ticker Nerd rank
29 / 100
Median analyst target
$52
Analysts covering
1
Revenue$0.0
Operating income−$2.0M
Net income−$2.0M
Free cash flow−$1.7M
Quarterly, 8 quarters to 31 May 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+36.7%
1M
+151.8%
YTD
+52.9%
1Y
−2.2%
From 52W high
−38.3%
From 52W low
+197.9%
$5
$23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LEXX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lexaria Bioscience Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Sept 2026
29 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
87
Accruals
68
Volatility
62
Revisions
42
Issuance
36
Growth
36
Momentum
33
Value
23
Quality
11

Size (87): Smaller than most of the companies we track.

Quality (11): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LEXX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LEXX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80Oct 25Jan 26Apr 26Jul 26LEXXHigh $82Median $52Low $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $22Median $52High $82

The green dot is the last close — the median target sits +271.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 Dec 2025HC Wainwright & Co.MaintainsBuy$4.00 → $1.50
29 July 2025HC Wainwright & Co.MaintainsBuy—
1 July 2025HC Wainwright & Co.MaintainsBuy—
24 Jan 2025HC Wainwright & Co.MaintainsBuy—
2 Dec 2024HC Wainwright & Co.ReiteratesBuy—
25 Nov 2024HC Wainwright & Co.ReiteratesBuy—
18 July 2024HC Wainwright & Co.ReiteratesBuy—
10 July 2024HC Wainwright & Co.InitiatesBuy—
5 Mar 2024Maxim GroupMaintainsBuy—
21 July 2023Maxim GroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LEXX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

LEXX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Sept 2026, Lexaria Bioscience Corp. returned −2.2% against +20.0% for the S&P 500, dividends included.

LEXX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140160Oct 25Jan 26Apr 26Jul 26LEXXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LEXX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Lexaria Bioscience Corp. (LEXX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.4×

Cheaper than 83% of US stocks

Price / sales
120.5×

Cheaper than 4% of US stocks

Price / book
4.9×

Cheaper than 22% of US stocks

EV / EBITDA
−2.6×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−3862.9%

Higher than 3% of US stocks

Net margin
99.6%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−162.8%

Higher than 9% of US stocks

Return on assets
−81.3%

Higher than 4% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Lexaria Bioscience Corp. (LEXX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Lexaria Bioscience Corp. has a market value of $23.4M and an enterprise value of $19.5M.

  • Revenue in the twelve months to 31 May 2026: $194K. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$7.7M, a −3989.9% net margin.

  • Free cash flow in the twelve months to 31 May 2026: −$7.5M.

  • Shares outstanding: 1.7M.

  • Trailing P/E: −1.4×; forward P/E: −36.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Lexaria Bioscience Corp. employs 7 people — $28K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 May 2026 · market figures as at 6 Sept 2026

Data provided by Twelve Data

Peers

LEXX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LEXXLexaria Bioscience Corp.$23.4M
29
PLRZPolyrizon Ltd.$23.4M
13
JSPRJasper Therapeutics, Inc.$23.6M
41
GRDXGridAI Technologies Corp.$23.0M
19
ALLRAllarity Therapeutics, Inc.$22.8M
28
LTRNLantern Pharma, Inc.$24.3M
53
CLRBCellectar Biosciences, Inc.$22.4M
26

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Lexaria Bioscience Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LEXX news & analysis

Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference

TheNewswire · 4 Sept 2026neutral

Lexaria Bioscience Corp. announced it will participate in the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026 in New York City. CEO Richard Christopher will deliver a company presentation and be available for one-on-one investor meetings throughout the event.

Why it matters — The presentation offers Lexaria exposure to investors and the wider financial community at a major investment conference, providing a platform to communicate its drug delivery platform directly.

Lexaria Receives USD$2.6 Million Tax Rebate Payment

TheNewswire · 1 Sept 2026positive

Lexaria Bioscience Corp. announced that it received a cash rebate of approximately AUD$3,666,611.98 (about USD$2.6 million) from the Australian Tax Office, related to its 2025 Australian human study. The funds were deposited into the account of its wholly-owned Australian subsidiary, Lexaria (AU) Pty Ltd.

Why it matters — The receipt of a significant cash rebate provides Lexaria with additional liquidity that could support its research and development activities.

DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2

Accesswire · 24 Aug 2026positive

Lexaria announced completed blood plasma pharmacokinetic testing for its 2026 Animal Study #2, which examined oral delivery of the next-generation GLP-1 drugs amycretin and retatrutide formulated with its patented DehydraTECH platform in tablets and capsules. The study reported that the DehydraTECH 3.0 amycretin tablet more than doubled absolute bioavailability versus a leading industry study, while the DehydraTECH 3.0 retatrutide tablet increased drug absorption by as much as 4,552% compared to the DehydraTECH 2.0 tablet.

Why it matters — The results provide evidence of DehydraTECH's benefits for oral delivery of next-generation GLP-1 drugs, which could support Lexaria's strategic partnering outreach activities.

Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know

Benzinga · 13 Aug 2026positive

Lexaria Bioscience Corp. (NASDAQ:LEXX) shares rallied Thursday after announcing a new Material Transfer Agreement with Hong Kong-listed PegBio Ltd.

Why it matters — The agreement with PegBio could signal a new strategic partnership or development milestone for Lexaria.

Lexaria Enters a Material Transfer Agreement With PegBio

Accesswire · 13 Aug 2026positive

Lexaria Bioscience has entered a Material Transfer Agreement with PegBio to evaluate its DehydraTECH drug delivery platform using a PegBio molecule being developed for the GLP-1 space. This agreement is separate from and unrelated to Lexaria's existing MTA with another pharmaceutical company.

Why it matters — This expands Lexaria's partnership pipeline within the high-demand GLP-1 drug sector without disrupting its existing agreements.

FAQ

Frequently asked questions about LEXX stock

What is the LEXX stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Lexaria Bioscience Corp. have a median 12-month price target of $52, with estimates ranging from $22 to $82. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LEXX stock a buy right now?

Of the 1 analysts covering Lexaria Bioscience Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Lexaria Bioscience Corp. 29 out of 100 across roughly 4,600 US stocks as at 5 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LEXX?

As at 5 Sept 2026, Lexaria Bioscience Corp. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (87 of 100).

Will LEXX stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +271.0% from the last close, and Ticker Nerd's factor model ranks Lexaria Bioscience Corp. 29 out of 100 as at 5 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LEXX stock forecast for 2030?

No analyst covering Lexaria Bioscience Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LEXX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $82 over the next 12 months.

How has LEXX stock performed over the past year?

Lexaria Bioscience Corp. returned -2.2% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lexaria Bioscience Corp. do?

Lexaria Bioscience Corp. is a biotechnology company focused on improving how active pharmaceutical ingredients are delivered and absorbed in the body.

What is the latest news on LEXX?

The most recent item we track (TheNewswire, 4 Sept 2026): "Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference". Lexaria Bioscience Corp. announced it will participate in the H.C. Wainwright 28th Annual Global Investment Conference, held September 14-16, 2026 in New York City. CEO Richard Christopher will deliver a company presentation and be available for one-on-one investor meetings throughout the event.

Company

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. is a biotechnology company focused on improving how active pharmaceutical ingredients are delivered and absorbed in the body. Its core platform, DehydraTECH, is designed to enhance oral bioavailability and can be applied across a range of compounds, including cannabinoids, nicotine, vitamins, pain medications, hormones, antivirals, and other lipophilic molecules. The company works through intellectual property licensing, business-to-business product development, and research and development activities, supporting pharmaceutical, nutraceutical, and consumer health applications. Lexaria Bioscience Corp. is headquartered in Kelowna, British Columbia, Canada, and its current work centers on developing and licensing drug delivery technologies for partners seeking more efficient oral formulations and improved therapeutic performance.

CEO Mr. Richard C. Christopher · 7 employees · Canada · https://lexariabioscience.com